These findings suggest that stathmin dynamics are closely related to the antiproliferative effects of eribulin and that stathmin may serve as a potential biomarker to predict the therapeutic effects of eribulin in breast cancer patients [42]. The gene discussed is STMN1; the disease is breast carcinoma.